Moreover, contemporary investigations have demonstrated that novel structural changes in FGFR2 and FGFR3 are frequently linked to an aggressive tumor biology and specific gene expression signatures, thus validating their function as powerful, clinically actionable drivers. Here, FGFR3 is linked to neoplasm.